{"id":"W2967622554","doi":"10.1111/ene.14056","title":"Patient‐reported outcomes with subcutaneous immunoglobulin in chronic inflammatory demyelinating polyneuropathy: the PATH study","year":2019,"lang":"en","type":"article","venue":"European Journal of Neurology","topic":"Peripheral Neuropathies and Disorders","field":"Medicine","cited_by":19,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; University Health Network","funders":"Japan Society for the Promotion of Science; Pfizer Japan; Grifols; Mitsubishi Tanabe Pharma Corporation; Bayer Yakuhin; Teijin Pharma; Prinses Beatrix Spierfonds; Ono Pharmaceutical; Eisai; Ministry of Education, Culture, Sports, Science and Technology; Shionogi; Argenx; Union Chimique Belge; Kissei; Boehringer Ingelheim Japan; Ministry of Health, Labour and Welfare; Japan Blood Products Organization; Bristol-Myers Squibb; CSL Behring; Kowa Company; European Commission; Pfizer","keywords":"Medicine; Chronic inflammatory demyelinating polyneuropathy; Placebo; Quality of life (healthcare); Internal medicine; Physical therapy; EQ-5D; Randomized controlled trial; Health related quality of life; Antibody; Immunology; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003189172,0.000771566,0.001119555,0.0003467964,0.0003031025,0.0005050913,0.0004392099,0.0009194757,0.003031721],"category_scores_gemma":[0.002331025,0.0002706001,0.001671684,0.0006208296,0.0006643222,0.0007003586,0.0008333618,0.001258363,0.0003235774],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004581002,"about_ca_system_score_gemma":0.0008683074,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005092652,"about_ca_topic_score_gemma":0.0006163495,"domain_scores_codex":[0.998447,0.001031279,0.00009205283,0.0001441315,0.0001815466,0.000104058],"domain_scores_gemma":[0.9972141,0.0008496053,0.001097931,0.0001590959,0.0001926577,0.0004865684],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.6389523,0.01293105,0.2484985,0.003505064,0.01050144,0.0003505721,0.0003984595,0.001655534,0.003331647,0.0002956232,0.002234199,0.07734567],"study_design_scores_gemma":[0.2087584,0.258765,0.5199409,0.000366872,0.005489732,0.0006510448,0.0003278208,0.00144052,0.0006486137,0.0003228635,0.003205405,0.00008280265],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956942,0.001989614,0.0001416864,0.0001495736,0.00003227604,0.0004603877,0.0009259525,0.000005742158,0.0006005645],"genre_scores_gemma":[0.9942607,0.001442866,0.0005195615,0.00020033,0.000127726,0.001437611,0.001525148,0.000003547497,0.0004825438],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003189172,"threshold_uncertainty_score":0.01686621,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.007972421909463312,"score_gpt":0.2277911404920299,"score_spread":0.2198187185825665,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}